Related Experiment Video
Updated: Jul 15, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
BCG pyelonephritis following intravesical therapy for transitional cell carcinoma
Jorge E Garcia1, David D Thiel, Gregory A Broderick
1Department of Urology, Mayo Clinic Jacksonville, Jacksonville, Florida 32224, USA.
Abstract:
Bacillus Calmette-Guerin (BCG) is a common intravesical agent utilized for superficial transitional cell carcinoma of the bladder. The potential for side effects and complications does exist secondary to the utilization of live attenuated bacteria. We present the case of a 70-year old male that developed BCG pyelonephritis and associated renal mass following the fifth of six weekly intravesical BCG therapies. The patient improved clinically and renal mass resolved following 3 months of isoniazid monotherapy without renal biopsy.
Related Concept Videos
Acute Pyelonephritis II: Diagnostic Studies and Management
Acute Pyelonephritis I: Introduction
Urinary Tract Infection II: Pathophysiology
Kidney Transplant II: Surgical Procedure
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
Imaging Studies V: Intravenous Urography and Retrograde Pyelography